SCHEMBL4449591

SCHEMBL4449591

CC/N=C/c1ccc2c(c1)OCO2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.54
ATM Q13315 1/20 0.54
ALDH1A1 P00352 5/20 0.53
KDM4E B2RXH2 2/20 0.53
ALOX15 P16050 1/20 0.53
HSD17B10 Q99714 2/20 0.53
TDP1 Q9NUW8 1/20 0.53
TP53 P04637 1/20 0.53
GRIN2D O15399 1/20 0.53
GRIN3B O60391 1/20 0.53
GRIN1 Q05586 1/20 0.53
GRIN2A Q12879 1/20 0.53
GRIN2B Q13224 1/20 0.53
GRIN2C Q14957 1/20 0.53
GRIN3A Q8TCU5 1/20 0.53
MAPT P10636 3/20 0.52
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4449592 1.00 CYP3A4 (0.54) CYP3A4ATMALDH1A1KDM4EALOX15
SCHEMBL3031855 0.87 ALDH1A1 (0.58) CYP3A4ATMALDH1A1KDM4EALOX15
SCHEMBL16704292 0.87 ALDH1A1 (0.58) CYP3A4ATMALDH1A1KDM4EALOX15
SCHEMBL4454927 0.84 ALDH1A1 (0.62) CYP3A4ATMALDH1A1KDM4EALOX15
SCHEMBL4454930 0.84 ALDH1A1 (0.62) CYP3A4ATMALDH1A1KDM4EALOX15
SCHEMBL3154846 0.80 CYP3A4 (0.59) CYP3A4ATMALDH1A1KDM4EALOX15
SCHEMBL4447859 0.80 CYP3A4 (0.59) CYP3A4ATMALDH1A1KDM4EALOX15
SCHEMBL7580330 0.80 ALDH1A1 (0.51) CYP3A4ATMALDH1A1KDM4EALOX15
SCHEMBL7575423 0.80 GRIN2D (0.50) CYP3A4ATMALDH1A1KDM4EALOX15
SCHEMBL7575421 0.80 GRIN2D (0.50) CYP3A4ATMALDH1A1KDM4EALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050452-A1 indenoisoquinolines as topoisomerase inhibitors I useful as antineoplastic agents Purdue Research Foundation (US) 2009-04-22 EP disclosed
US-6509344-B1 A method for treating a patient having cancer, said method comprising the step of administering to the patient an effective amount of a compound according to claim 1, whereupon said patient is treated for cancer, and wherein the cancer is THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES 2003-01-21 US disclosed
EP-1123099-A4 NOVEL INDENOISOQUINOLINES AS ANTINEOPLASTIC AGENTS PURDUE RESEARCH FOUNDATION (US) 2002-08-21 EP disclosed
EP-1123099-A1 NOVEL INDENOISOQUINOLINES AS ANTINEOPLASTIC AGENTS PURDUE RESEARCH FOUNDATION (US) 2001-08-16 EP disclosed
WO-2000021537-A1 NOVEL INDENOISOQUINOLINES AS ANTINEOPLASTIC AGENTS PURDUE RESEARCH FOUNDATION (US) 2000-04-20 WO disclosed